Übersicht

Dermato-Onkologie-Nachwuchspreis der ADF

- gestiftet von der Erwin + Irmgard-Egner Stiftung

Im Jahr 2025 ist es der ADF möglich, zwei Nachwuchspreise für wissenschaftliche Arbeiten auf dem Gebiet der Dermato-Onkologie zu vergeben. Diese Preise werden von der Erwin + Irmgard-Egner Stiftung gestiftet.

Es nehmen alle onkologischen Beiträge (Poster / Vortrag) teil, die fristgerecht zur ADF-Jahrestagung eingereicht werden. Der Preis wird einem Erstautor bzw. einer Arbeitsgruppe verliehen, die den prämierten Beitrag gemeinsam erarbeitet hat. Die Auszeichnung ist nicht abhängig von der ADF-Mitgliedschaft der Autoren.

Der Preis ist mit je 2.500 € dotiert.

Die Preisverleihungen finden während der ADF-Tagung statt. Die Preisträger werden von einer unabhängigen Jury ausgewählt, die alle drei Jahre vom ADF-Vorstand gewählt wird.

An den Preis ist die Einreichung/Veröffentlichung eines kurzen Reports im Experimental Dermatology gebunden.

Kuratorium:

  • Prof. Dr. rer. nat. Patrizia Stoitzner (Vorsitz)
  • Prof. Dr. med. Tobias Bald
  • Prof. Dr. med. Christoffer Gebhardt
  • Prof. Dr. rer. nat. Iris Helfrich
  • Prof. Dr. med. Jan Nicolay
  • Prof. Dr. med. Carsten Weishaupt

Bisherige Preisträger des Dermato-Onkologie-Nachwuchspreis der ADF

2025
Antonia Kolb, Mainz
P225: Constitutive expression of IκBζ promotes tumor growth and immunotherapy resistance in melanoma
2025
Antonia Stubenvoll, Leipzig
P262: An investigation of melanoma immunity using single-cell multiomics: Novel cell-cell communication partners and their antitumoral role
2024
Simona Saluzzo, Wien
P168: A subsets of skin resident CD8+ T cells protects organ transplant receivers from skin cancer development
2024
Saskia Vadder, Bonn
P190: The Influence of Nras and Trp53 Point Mutations on Melanoma Plasticity and the Tumor Microenvironment
2024
Mette Purde, St. Gallen
P204: Propagating viral vector-based vaccine platform as potent therapeutic strategy for solid tumor elimination
2024
Luiza Martins Nascentes Melo, Essen
P209: Selenoprotein O regulates melanoma metastasis through mitochondrial complex II activity
2024
Luisa Bopp, Köln
P214: Metabolite-driven regulation of T cells in human keratinocyte-derived skin cancer
2023
Sheena. Daignault-Mill, Woolloongabba
P211: Overcoming Immune Checkpoint Inhibitor Resistance to Improve Melanoma Therapy
2023
Florian Hornsteiner, Innsbruck
P200: The role of dendritic cells in tumor-targeted therapy mediated anti-tumor immunity
2023
Anthony Buzzai, Magdeburg
P108: Tumour-specific CD4+ T cells recruit inflammatory monocytes that acquire IFN-activated functions to control immune evasive tumours
2022
Corinne Huebers, Mannheim
P209: nAngiopoietin-like 4 inhibits metastasis formation
2022
Jan-Malte Placke, Essen
P199: Inhibition of the mTOR inhibitory protein sirtuin 1 leads to faster tumor growth under PD1-based immune checkpoint blockade
2021
Fang Zhao, Essen
P102: Profiling of tumor-infiltrating T cells for guidance of melanoma salvage therapy in immune-checkpoint-blockade resistant patients
2021
Yuanyuan Wang, Hamburg
P191: Heparan sulfate dependent binding of melanoma cells to plasmatic von Willebrand factor attenuates melanoma metastasis
2021
Dennis Gerloff, Halle/S.
P213: Melanoma derived extracellular vesicles deliver miRNAs as molecular switches in macrophage activation
2020
Nicht vergeben
2019
Alexander Thiem, Würzburg
P186: p53 is involved in basal and IFN-gamma induced PD-L1 expression in melanoma
2019
Corinna Kosnopfel, Tübingen
P198: Inhibition of RSK family members can effectively target malignant melanoma cells with MAPK pathway hyperactivation
2018
Agnes Forsthuber, Wien
A dual role of neutrophils in cutaneous melanoma
2018
Bianca Simon, Erlangen
The simultaneous siRNA-mediated downregulation of PD-1 and CTLA-4 to improve CAR-T cell immunotherapy of melanoma
2018
Naveen Shridhar, Bonn
Effect of selective Gq/11-inhibition on malignant melanoma
2017
York Kamenisch/Tarza Baban, Regensburg
Ultraviolet (UV)-A irradiation induces melanoma invasion via enhanced Warburg effect
2017
Oana-Diana Persa, Köln
Dual role of aPKC/ in skin carcinogenesis
2017
Mirko Gries, Heidelberg
Damage-associated molecular pattern molecules as novel predictive markers in melanoma treatment with immune checkpoint inhibitors
2016
Ellen Brenner, Tübingen
Stat1-induced cancer cell senescence protects from metastases
2016
Stefanie Riesenberg, Bonn
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment
2016
Christian Posch, Wien
Phospho-proteomic analysis reveals increased CK2alpha kinase activity in NRAS(Q61) mutant melanoma
2015
Katharina Amschler, Göttingen
Melanoma cells adapt flexibly to variation of N- and E-cadherin-density on the nanoscale
2015
Heike Niessner, Tübingen
The BRAF inhibitor LGX818 (encorafenib) induces endoplasmic reticulum stress and sensitizes NRAS-mutant melanoma cells to the MEK inhibitor binimetinib
2015
Bastian Schilling/Klaus Griewank, Essen
Dual immune checkpoint blockage delays GNAQ-driven tumor growth in an autologous murine uveal melanoma model
2014
Andrea Tüttenberg, Mainz
Molecules associated with T regulatory cell function are highly expressed on melanoma: Novel targets for immunotherapeutic strategies (P133)

Nanoparticular targeting of tolerance inducing macrophages, DC and myeloid suppressor cells - new strategies for therapeutic approaches in immune-mediated diseases (P154)
2014
Tobias Sinnberg, Tübingen
Hypoxia confers resistance towards ascorbate-induced ROS-driven cytotoxicity in melanoma cell lines (P286)

Canonical Wnt signalling enhances neural crest migration in zebrafish and epithelial mesenchymal transition associated melanoma cell invasion (P289)

Beta-catenin in the course of aquired resistance to the BRAFV600E inhibitor vemurafenib in malignant melanoma (P291)
2013
Amir Yazdi, Tübingen (Nachwuchspreis)
Contrasting, cell type-specific role of ASC in epithelial skin cancer
2013
Iris Helfrich, Essen (Nachwuchspreis)
Neuropilin-1 deficiency on CD4+Foxp3+ regulatory T cells impaires tumor growth in melanoma
2012
Johanna Kaufmann, Heidelberg (Nachwuchspreis)
Specific killing of melanoma cells by infection with an oncolytic measles virus directed to the surface antigen HMWMAA
2012
Maria Feoktistova und Peter Geserick, Mannheim (Nachwuchspreis)
The Ripoptosome - a novel molecular complex differentially regulated by cFLIP isoforms and a critical switch between apoptotic and necroptotic cell death in skin tumor cells
2011
Carola Berking, München (Hauptpreis)
Molekulare Mechanismen beim malignen Melanom
2011
Jenny Landsberg, Bonn (Nachwuchspreis)
T cell mediated immune surveillance promotes melanoma cell dedifferentiation in the genetically engineered Hgf-Cdk4R24C mouse model
2011
Christian Busch, Tübingen (Nachwuchspreis)
Bone morphogenetic protein and nodal regulate adhesion and migration in melanoma cells and confer a malignant phenotype to melanocytes in vitro and in vivo
2010
AG Birgit Schittek, Tübingen (Hauptpreis)
Molekulare Mechanismen der Melanomentstehung
2010
Sebastian Haferkamp, Würzburg (Nachwuchspreis)
Oncogene-induced senescence of primary human melanocyte
2010
Silke Kuphal, Regensburg (Nachwuchspreis)
Persistent NFkappaB activation in malignant melanoma is generated through loss of the tumor suppressor CYLD
2009
AG Jürgen Eberle, Berlin
2008
Petra Boukamp, Heidelberg
2007
Selma Ugurel-Becker, Würzburg
2006
Erwin S. Schultz, Marburg